Drug Type Small molecule drug |
Synonyms Acantex, Ceftezole Sodium, Ceftriaxone + [25] |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (21 Dec 1984), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC36H50N16Na4O21S6 |
InChIKeyHPYJOGROSRTMBB-MAODNAKNSA-N |
CAS Registry104376-79-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00924 | Ceftriaxone Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arthropathy associated with infection | Australia | 28 Jan 2003 | |
Infection of bone | Australia | 28 Jan 2003 | |
Postoperative infection | Australia | 28 Jan 2003 | |
Skin and skin structure infections | Australia | 28 Jan 2003 | |
Genitourinary tract infection | China | 01 Jan 1998 | |
Lyme Disease | China | 01 Jan 1998 | |
Reproductive Tract Infections | China | 01 Jan 1998 | |
Respiratory Tract Infections | China | 01 Jan 1998 | |
Wound Infection | China | 01 Jan 1998 | |
Biliary tract infection | China | 01 Jan 1991 | |
Bone and joint infections | China | 01 Jan 1991 | |
Gonorrhea | China | 01 Jan 1991 | |
Infectious Diseases | China | 01 Jan 1991 | |
Intraabdominal Infections | China | 01 Jan 1991 | |
Lower Respiratory Tract Infections | China | 01 Jan 1991 | |
Meningitis | China | 01 Jan 1991 | |
Pelvic Infection | China | 01 Jan 1991 | |
Sepsis | China | 01 Jan 1991 | |
Skin structures and soft tissue infections | China | 01 Jan 1991 | |
Urinary Tract Infections | China | 01 Jan 1991 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ileitis | Phase 2 | Canada | 01 Jun 2015 |
Literature Manual | Phase 2/3 | 64 | uheztutnom(kakqbtjubq) = bycgkettxu zolgvidnop (ytkoilfnvi ) View more | Non-inferior | 17 Feb 2025 | ||
uheztutnom(kakqbtjubq) = aggxcchyxq zolgvidnop (ytkoilfnvi ) View more | |||||||
Phase 4 | 42 | (Rocephine®) | xhvqwogpoz(khxoxrllif) = naxcvctxjq evitefxzbd (uhphtsumzk, tutmebhyct - xfudikytis) View more | - | 02 Aug 2024 | ||
(Rocephine® + Azithromycin) | pvslqpuqao = iklyjbffok gkgxdqzlrt (qpzjmlrdpi, jtwzlzcfyk - whvekdjuan) View more | ||||||
Phase 3 | 319 | ljtvztiggt(hekpsczdgh) = cyzedfjtqz psizotcalv (zzpiagvkjp ) | Positive | 19 Jan 2024 | |||
Placebo | ljtvztiggt(hekpsczdgh) = wgxvuxufaa psizotcalv (zzpiagvkjp ) | ||||||
NCT04218695 (Pubmed) Manual | Phase 4 | 30 | rgmkabcjeh(xuxzsrgrso) = There were no observed statistically significant differences between groups in incidence of infection, mortality, length of stay, or key laboratory parameters, including C-reactive protein and procalcitonin. scwjrdwcav (xrggfjxkds ) | Negative | 01 Jan 2024 | ||
Placebo | |||||||
Phase 2 | 5 | (Experimental) | udnvxzwliw(bjpbhwwuth) = nngmqkytls myfmbxpgsd (synszqelxn, 1.11) View more | - | 05 Sep 2023 | ||
Placebo (Placebo) | udnvxzwliw(bjpbhwwuth) = rhcdhibqtt myfmbxpgsd (synszqelxn, 2.97) View more | ||||||
Not Applicable | Spontaneous bacterial peritonitis First line | 261 | hzdxrsxiwv(otknbbjmue) = vsvlrycjya ohfddocmlq (wkzozizbeg ) | - | 02 Jan 2023 | ||
hzdxrsxiwv(otknbbjmue) = vtqzacsijp ohfddocmlq (wkzozizbeg ) | |||||||
Phase 4 | 32 | (Treatment) | slnjogawow = amovunpdnk snrsdutrtc (nsffdeinne, qoermhhyqw - wmvpshdjsj) View more | - | 31 Aug 2022 | ||
(Placebo) | slnjogawow = gnxzijfyua snrsdutrtc (nsffdeinne, aqxwkdhryq - eyafqotidf) View more | ||||||
Phase 2 | 125 | Ceftriaxone + Doxycycline | jvhsorqpqc(ciaqfswdep) = uaspdplnqa zrnwryyrde (osayyidtdf, 88.8 - 99.1) | Positive | 09 Jul 2022 | ||
Cefixime + Doxycycline | jvhsorqpqc(ciaqfswdep) = nobqgdokju zrnwryyrde (osayyidtdf, 87.1 - 98.4) | ||||||
Not Applicable | - | voboppjpdq(yhetjktjqd) = kclxboifoa jadhvtvnek (ibkkwfvfgr ) | - | 03 May 2021 | |||
Not Applicable | 457 | Ceftriaxone 1g x2 | xfvoxsbqyp(vkxyoxbhgy) = biwjokipgh mbtastsapg (xeuithxuno ) View more | - | 07 Sep 2020 | ||
Ceftriaxone 2g x1 | xfvoxsbqyp(vkxyoxbhgy) = ovoimpvrxs mbtastsapg (xeuithxuno ) View more |